Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 8/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6788458 | 0.88 | DRD4 (0.59) | DRD4HRH4DRD2DRD3HTR1A | |
| SCHEMBL30041257 | 0.82 | HRH4 (0.63) | DRD4HRH4DRD2DRD3HTR1A | |
| SCHEMBL6782457 | 0.79 | HRH4 (0.63) | DRD4HRH4DRD2DRD3HTR1A | |
| SCHEMBL4810808 | 0.78 | DRD4 (1.00) | DRD4DRD2HTR1AHTR2AHTT | |
| SCHEMBL6782261 | 0.76 | HRH4 (0.59) | HRH4DRD3KMT2A | |
| SCHEMBL30041328 | 0.76 | HRH4 (0.69) | DRD4HRH4DRD2DRD3HTR1A | |
| SCHEMBL4520581 | 0.76 | KMT2A (0.61) | DRD4DRD2DRD3HTR1AHTT | |
| SCHEMBL8682915 | 0.76 | HRH4 (0.69) | DRD4HRH4DRD2DRD3HTR1A | |
| SCHEMBL28962397 | 0.75 | HRH4 (0.57) | DRD4HRH4DRD2DRD3HTR1A | |
| SCHEMBL24159809 | 0.75 | HRH4 (0.54) | DRD4HRH4DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | PFIZER INC. | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100757-A1 | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor | DRD2, DRD3, DRD4 | DRD4 3/4885HRH4 151/4885DRD2 1/4885 |
| US-20040198734-A1 | 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine | DRD2, DRD3, TPH1 | DRD4 6/4885HRH4 344/4885DRD2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.